Premium
AMD Drusenoid deposits characterization: Interest of OCT, OCT en FACE
Author(s) -
GONZALEZ C
Publication year - 2013
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2013.f043.x
Subject(s) - drusen , fundus (uterus) , ophthalmology , medicine , retinal , macular degeneration , geology
Purpose To study AMD drusenoid deposits with OCT en Face and see all the input of this technique and software Methods 204 eyes of 102 patients, 32 men, 70 women, with AMD drusenoid deposits (Cuticular drusen, Subretinal drusenoid deposits, soft Drusen, Drusenoid PED,Pseudovitelliform AMD). Deposits were evaluated by OCT, notably OCT en FACE (Spectralis HRA‐OCT, spectral domainOCT). Autofluorescence, IR imaging, ETDRS visual acuity (VA), complete ophthalmic examination with Fundus exam were added. The size, characteristics, number, topography of the lesions, their growth way were evaluated, as well as their environment above and below (particularly IS‐OS, plexiform layer, choriocapillaris structure and thickness). Each element was studied, compared cut to cut, layer to layer and time to time to itself and to each other data, every 4 months. Results VA improved in 85% cases, stabilized in 15%. AF imaging and their region finder analyze were the main elements of the atrophic lesions’ study. The surface of the atrophic area grows by 17%, the edge changes in 20%. Speed growth was in average 1,15mm2/year. At OCT, thickness of photoreceptor, pigment epithelium layer diminished about 25% and 35% at the area’s edge. Choriocapillary depth values, FA and ICG data were mainly significative in the large atrophic areas and less than AF indications. This protocol has a little impact on the evolution of atrophic areas, apparently less than monthly IVT, and the same as AMD by itself. Conclusion The study of atrophic process and its progression is a main question in the AMD follow –up, the evaluation of the protocol treatments and their safety too.